article Open AccessTop 10% cited

Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma

BMC Cancer · 2017 · Vol. 17(1) · pp. 434–434

Anderson Hudgens Webb(University of Tennessee Health Science Center)Bradley T Gao(University of Tennessee Health Science Center)Zachary K. Goldsmith(University of Tennessee Health Science Center)Andrew Irvine(University of Tennessee Health Science Center)Nabil Saleh(University of Tennessee Health Science Center)Ryan P. Lee(University of Tennessee Health Science Center)Justin B Lendermon(University of Tennessee Health Science Center)Rajini Bheemreddy(University of Tennessee Health Science Center)Qiuhua Zhang(University of Tennessee Health Science Center)Rachel C. Brennan(University of Tennessee Health Science Center)Dianna A. Johnson(University of Tennessee Health Science Center)Jena J. Steinle(Wayne State University)Matthew W. Wilson(St. Jude Children's Research Hospital)Vanessa Morales-Tirado✉(University of Tennessee Health Science Center)

View via DOI Full-text PDF

Abstract

Collectively, our data indicates MMP-2 and MMP-9 drive metastatic pathways, including migration, viability and secretion of angiogenic factors in Rb cells. These two subtypes of matrix metalloproteinases represent new potential candidates for targeted anti-metastatic therapy for Rb.

Protease and Inhibitor Mechanisms Ubiquitin and proteasome pathways Multiple Myeloma Research and TreatmentsRetinoblastomaMatrix metalloproteinaseMetastasisMedicineCancer researchExtracellular matrixAngiogenesisSurgical oncologyMatrix metalloproteinase inhibitorIntravasation

MeSH terms

Cell MovementCell SurvivalHumansNeovascularization, PathologicRetinoblastomaMatrix Metalloproteinase 2Matrix Metalloproteinase 9Vascular Endothelial Growth Factor ACell Line, TumorMatrix Metalloproteinase Inhibitors